Tag: avxl

Anavex to Participate in Mizuho Therapeutics Conference

NEW YORK, Sept. 14, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will participate in Mizuho Therapeutics Conference on Wednesday, September 21, 2016. The conference will be held at the Langham Hotel in Boston, Massachusetts. Investors interested in attending may contact the conference organizers or Anavex Investor Relations. About Anavex Life Sciences Corp.

Anavex Reports Fiscal Third Quarter 2016 Financial Results

NEW YORK, Aug. 11, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and nine months ended June 30, 2016. Highlights: The SEC staff recently advised Company’s legal counsel that the staff did not intend to recommend enforcement action by the Commission against the Company in connection with the investigation previously described in the Company’s 2015 Report on Form

Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016

NEW YORK, July 29, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer’s trial for ANAVEX 2-73. Dr. Norman Relkin, MD, PhD, an Alzheimer clinical trialist and an advisor to Anavex, commented:  “To interpret the ANAVEX 2-73 results presented at the 2016 AAIC meeting, it is important to keep in mind the stated goals of this first in Alzheimer’s patients study.  This was a Phase 2a study, primarily designed to determine which ANAVEX 2-73 dosages are safe to

Anavex Presents New Data on Preclinical Development of ANAVEX 3-71

NEW YORK, March 14, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive preclinical data on sigma-1 agonist ANAVEX 3-71 (formerly AF710B).  The results show a statistically significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. The poster, titled “AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible disease-modifying properties in McGill-R-Thy1-APP rats,”

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Anavex Life Sciences Corp. and a Lead Plaintiff Deadline of February 29, 2016 – AVXL

NEW YORK, Feb. 19, 2016 (GLOBE NEWSWIRE) — The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Anavex Life Sciences Corp. (NASDAQ:AVXL) securities between May 17, 2013 and December 28, 2015. Click here to learn about the case: http://docs.wongesq.com/AVXL-Info-Request-Form-1048. There is no cost or obligation to you. According to the complaint, Anavex issued misleading statements and failed to disclose that the Company had used a paid stock promoter to artificially inflate the Company’s share price. On December 29,

The Buzz on $AVXL – #Anavex – Investigation, Discovery & Shareholders!

I’m sure you all know that we have covered Anavex Holdings $AVXL since at least May. Likely before most of you ever heard of it. We’ve never held a position and we’ve never been compensated. We followed it for the upside we saw, as this stock was heavily promoted. Now, we see the downside as kicking in. Don’t be left holding here, if you value your investment.    The Buzz on Twitter:  [cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] Profit Trade Room ‏@ProfitTradeRoom  $AVXL oops, told you this stock is crash and short is the only right thing to do! Hope you’ll listen

Globe Newswire

News $AVXL – #Anavex Reports Fiscal First Quarter 2016 Financial Results

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] NEW YORK, Feb. 08, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three months ended December 31, 2015. Financial Highlights: Anavex had cash and cash equivalents of approximately $13.8 million as of December 31, 2015, compared to approximately $15.3 million as at September 30, 2015. Anavex used approximately $1.5 million in net cash during the first

Buzz

Huge News $AVXL – #Anavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer’s Disease Patients

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] NEW YORK, Jan. 11, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported a positive dose-response relationship has been observed in a pre-planned interim analysis of data from the ongoing Phase 2a trial of ANAVEX 2-73 for treatment of mild to moderate Alzheimer’s disease. The change in Mini Mental State Examination score (MMSE-Δ) (MMSE difference recorded for every single study subject

Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. and Certain Officers – AVXL

NEW YORK, Dec. 30, 2015 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”)(NASDAQ:AVXL), and certain of its officers.   The class action, filed in United States District Court, Southern District of New York, and docketed under 15-cv-10162, is on behalf of a class consisting of all persons or entities who purchased Anavex securities between May 17, 2013 and December 28, 2015 inclusive (the “Class Period”).  This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange

Blog

Trade Alert: Price for $RXSF Creates Potential Upside Gain of 161% if Reaches 5-Day High Again

  NOTE: This company now trades as GeneSYS ID, Inc. (OTCQB: GNID). .. We see the chart for RX Safes, Inc. (OTCQB: RXSF) acting very similar to Anavex Life Sciences Corporation (Nasdaq: AVXL).  RXSF was over $7 just days ago, and now it dipped to a level where someone buying in at or below $2.75 has a potential gain of 140% should the stock return to its recent high.  Shares for RXSF act a lot like AVXL, as it moves up and down, then further up…. repeating this pattern over and over.  I am a consultant to the Company. I came on knowing of

Anavex Announces Fiscal 2015 Year-End Financial Results

NEW YORK, Dec. 29, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported year-end results for fiscal year 2015. Financial Highlights: Anavex had cash and cash equivalents of $15.3 million as of September 30, 2015, compared with $7.3 million as at September 30, 2014. During fiscal year 2015 Anavex used $4.2 million in cash to fund operations. The net loss for fiscal year 2015 was $12.1

Blog

The Buzz is Positive on $AVXL as it Continues to Hold Most of the Early Gains

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/]   Yes, the Buzz is strong today for Anavex Life Sciences Corp. (NASDAQ: AVXL). So far we have seen the stock as high as $7.14. While volume is light, it was only held back, in our opinion, by the upward movement in the price early on.  Let’s Get the Buzz Around the Markets… Here’s Twitter:      Tanner has been very active today in posting:  Tanner Schulze ‏@TJschulze $avxl closing about $7 today  Tanner Schulze ‏@TJschulze I strongly believe with upcoming 12 week news $AVXL will trade into $10. Everything is positive and should gap up.

Anavex Expands Management Team

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] NEW YORK, Dec. 02, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Ulrich Elben, PhD as Vice President of Preclinical Operations.  In this new role, Dr. Elben will oversee the pipeline development and optimization. “What attracted me to join Anavex is the very impressive pipeline consisting of potential breakthrough therapies for indications with very high unmet medical need like Alzheimer’s disease and

Independent Research Describes ANAVEX 3-71 as Potent Cognitive Enhancer in Alzheimer’s Disease Models

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] NEW YORK, Nov. 30, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer, announced today the publication of further data for ANAVEX 3-71 (formerly AF710B) in the peer-reviewed scientific journal Neurodegenerative Diseases.  The ANAVEX 3-71 data provides evidence for a positive, more upstream effect on reducing synaptic loss, amyloid and tau pathologies, and neuroinflammation, which is potentially beneficial for the treatment of Alzheimer’s and other neurological diseases. 

Anavex Announces Preparation of Regulatory Filings Based on Guidance From the FDA

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] NEW YORK, Nov. 18, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces that it is moving forward with the development program for ANAVEX 2-73.  Guidance received from the FDA confirms the Company’s strategy to advance ANAVEX 2-73 for the treatment of Alzheimer’s disease in a larger double-blinded, randomized, placebo-controlled Phase 2/3 trial. “Working with a highly vulnerable patient population, the Company is proceeding in a rational,

Anavex Announces CTAD 2015 Abstract

NEW YORK, Nov. 05, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, is pleased to announce that the abstract for its presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Barcelona, Spain on Saturday, November 7, 2015 is now available online. The late-breaking oral session will be presented by the

Buzz

The Buzz only Get’s Bigger as $AVXL is now on Nasdaq and the Price Closes in on $15!

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] Yes, we’ve been all over Anavex Life Sciences Corp (NASDAQ: AVXL, AVXLD recently) for MONTHS.  Since we started, things have gone from very good to GREAT. Things have gone from Over the Counter to Nasdaq. We have a lot of happy members… but forget about us!  Let’s get the real buzz out there as this one tries to conquer and finally go above $15 forever. Didn’t quite make it today. At least we got rid of the D and can enjoy four letter trading again! The Buzz:   Churbz thinks the best thing to do is

Anavex Life Sciences Corp. (Nasdaq:AVXL) to Ring The Nasdaq Stock Market Closing Bell

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] ADVISORY, Oct. 29, 2015 (GLOBE NEWSWIRE) — What:  Anavex Life Sciences Corp. (Nasdaq:AVXL), a clinical-stage biopharmaceutical company that is developing drug candidates for Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, will visit the Nasdaq MarketSite in Times Square to celebrate its recent listing on the Nasdaq Capital Market. In honor of the occasion, Christopher U. Missling, PhD, President and Chief Executive Officer will ring the Closing Bell.  Where: Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio When: Friday, October 30, 2015 – 3:45

Buzz

Buzz on $AVXL $AVXLD – Is StockGuru Behind This Momentum? Find Out Here! #ANAVEX

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] I will admit this one post is pure click bait. I keep getting asked this question: “Are you being paid to promote Anavex Life Sciences Corp.  (Nasdaq!: AVXL / AVXLD)?” Here’s an answer I put on Twitter answering “StockMarketNietzsche”  /aka/ ‏@Investor4201: As you can see I am not and never have been paid by anyone to promote or publish on AVXL. It has generated a ton of hits. Likely there are ads on my site that were clicked during the 5000 plus visits, but that would never count as compensation from AVXL.    Second question: